Research Topics
Species | John P HoustonSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproexJohn P Houston
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46221, USA
J Clin Psychiatry 67:1246-52. 2006..To identify symptoms associated with suicidality in bipolar I disorder patients, and to assess suicide risk during treatment with olan-zapine in combination with lithium or divalproex...
Symptoms predicting remission after divalproex augmentation with olanzapine in partially nonresponsive patients experiencing mixed bipolar I episode: a post-hoc analysis of a randomized controlled studyJohn P Houston
US Medical Neuroscience, Lilly USA, LLC Drop Code 4133, Indianapolis, IN 46285 USA
BMC Res Notes 3:276. 2010..At baseline, the two treatment groups were similar...
Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled studyJohn P Houston
Lilly USA, LLC, Drop Code 4133, Indianapolis, IN 46285, USA
J Clin Psychiatry 70:1540-7. 2009....- Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodesJohn P Houston
US Medical Neuroscience, Lilly USA, LLC, Drop Code 4133, Indianapolis, IN 46285, USA
J Psychiatr Res 45:169-73. 2011..Because remission with augmentation therapy may occur in as few as one in ten individuals who lack very early symptom reduction, lack of early improvement may indicate a need to expediently reassess treatment strategy... - Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated womenJohn Houston
Lilly USA LLC, Indianapolis, IN, USA
Psychiatry Res 187:74-9. 2011..Five of these SNPs fall in or are adjacent to an LD block spanning DRD2 intron 7, exon 7, 5' untranslated region and ANKK1. Clinical trial Registration: www.clinicaltrial.gov... - PDI-4A: an augmented provisional screening instrument assessing 5 additional common anxiety-related diagnoses in adult primary care patientsJohn P Houston
Lilly USA, LLC, Indianapolis, IN 46285, USA
Postgrad Med 123:89-95. 2011..The PDI-4A may additionally help primary care physicians identify patients with PA, SP, OCD, hypochondriasis, and PTSD... - Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithiumJohn P Houston
Lilly Corporate Center, Lilly Research Laboratories, Drop Code 4133, Indianapolis, IN 46285, United States
J Psychiatr Res 41:616-21. 2007.... - Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophreniaJohn P Houston
Eli Lilly and Company, Indianapolis, Indiana, USA
J Clin Psychiatry 73:1077-86. 2012..We assessed the relationships between single-nucleotide polymorphisms (SNPs) in these genes with weight gain during treatment with olanzapine in a predominantly antipsychotic-naive population... - Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patientsJohn P Houston
Lilly USA, LLC, Indianapolis, IN 46285, USA
Psychiatry Res 175:171-2. 2010..In both cohorts, three dopamine receptor D2 (DRD2) SNPs were associated with prolactin changes. DRD2 may influence susceptibility to hyperprolactinemia associated with antipsychotic treatment... - Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysisJohn P Houston
Lilly USA, LLC, Indianapolis, IN 46285, USA
J Clin Psychiatry 73:878-85. 2012..To determine whether single-nucleotide polymorphisms (SNPs) in candidate genes are associated with response to olanzapine-fluoxetine combination... - Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approachIlya A Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Psychiatry Res 170:161-7. 2009..Early symptom response significantly improved the prediction of outcome, suggesting that early monitoring of treatment response may be useful in clinical practice... - Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depressionEileen Brown
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Int J Neuropsychopharmacol 12:773-82. 2009..There was no treatment difference in incidence of relapse. OFC-treated patients had more treatment-emergent adverse events and greater incidence of weight gain and hypercholesterolaemia... - A provisional screening instrument for four common mental disorders in adult primary care patientsJohn P Houston
Lilly USA, LLC, Indianapolis, IN 46285, USA
Psychosomatics 52:48-55. 2011..To develop an adult self-report instrument for provisional diagnosis of four common mental disorders in primary care patients... - The association of single nucleotide polymorphisms in the catechol-O-methyltransferase gene and pain scores in female patients with major depressive disorderBonnie Fijal
Eli Lilly and Company Lilly Corporate Center, Indianapolis, Indiana, USA
J Pain 11:910-5, 915.e1-9. 2010..This finding could potentially help clinicians who seek to assess how genetic polymorphisms may contribute to a patient's pain experience... - Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorderDavid H Adams
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Hum Psychopharmacol 23:267-74. 2008..To test association of dopamine receptor D3 (DRD-3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial... - Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidoneBonnie A Fijal
Lilly USA, Indianapolis, IN 46285, USA
J Clin Psychiatry 73:367-71. 2012..We examined 6 single nucleotide polymorphisms (SNPs) previously reported to be associated with response to iloperidone therapy for association with response to risperidone therapy... - Evaluating dose response from flexible dose clinical trialsIlya Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis Indiana, USA
BMC Psychiatry 8:3. 2008..The true dose effect in flexible-dose clinical trials may be obscured and even reversed because dose and outcome are related... - Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorderJohn P Houston
Neuroscience Department, Eli Lilly and Company, LLC, Indianapolis, IN, USA
Psychiatry Res 189:475-7. 2011..COMT rs165737 and a diplotype containing COMT rs165599 and COMT rs165737 were associated with HAMD(17) total score changes... - Early predictors of substantial weight gain in bipolar patients treated with olanzapineIlya Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 26:316-20. 2006..Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation... - Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approachIlya A Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA
BMC Psychiatry 8:65. 2008..The objective of this exploratory analysis was to characterize response in bipolar disorder by identifying groups of patients with similar manic symptom response profiles... - Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)Craig H Mallinckrodt
Lilly Research Laboratories, Indianapolis, Ind 46285, USA
Neuropsychobiology 56:73-85. 2007.... - Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorderJohn P Houston
Lilly USA, LLC, US Medical Neuroscience Department, Indianapolis, IN 46285, USA
Psychiatry Res 200:63-5. 2012..020) of a composite risk score (based on SLC6A2 rs5569 [G1287A] AA, HTR1A rs6295 [C(-1019)G] GG, and COMT rs174697 AA/AG) with 17-item Hamilton Depression Rating Scale total score change from baseline to 12 weeks was observed... - Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital databaseKaren C Holdridge
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
Curr Drug Saf 5:203-11. 2010..73, 95% CI 0.57-0.93; p=.011). The results suggest that patients treated with IM olanzapine do not have a significantly greater risk of death than patients treated with IM haloperidol or IM ziprasidone... - A cross-validation of the provisional diagnostic instrument (PDI-4)Douglas E Faries
Lilly Research Laboratories, Indianapolis, IN, USA
BMC Fam Pract 13:104. 2012..Our objective was to assess validity of the PDI-4 in a population independent of the study population originally used to develop the scale... - Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophreniaJohn P Houston
J Clin Psychopharmacol 27:520-3. 2007 - An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorderFranca Centorrino
McLean Hospital, Harvard Medical School, Boston, MA, USA
Hum Psychopharmacol 22:455-62. 2007..To determine the effect of intramuscular (IM) olanzapine in severely agitated patients... - Association of acute symptoms and compliance attitude in noncompliant patients with schizophreniaHong Liu-Seifert
J Clin Psychopharmacol 27:392-4. 2007 - Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodesTerence A Ketter
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
J Clin Psychiatry 67:95-101. 2006..Thus, olanzapine maintenance therapy may be particularly effective early in the course of bipolar illness... - A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophreniaJohn Battaglia
Program of Assertive Community Treatment, Madison, WI 53703, USA
Clin Ther 27:1612-8. 2005..Acutely agitated patients with schizophrenia might require treatment with IM antipsychotics, followed by a transition to oral medication... - A video method for the evaluation of antidepressant clinical and behavioural actionsMartin M Katz
Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA
Int J Neuropsychopharmacol 9:327-36. 2006..e. effect motor activity and depressed mood, and paroxetine to reduce global severity and anxiety. The study shows the VIBES to be capable of uncovering behavioural mechanisms underlying AD's capacity to resolve depressive disorder... - A multivantaged behavioural method for measuring onset and sequence of the clinical actions of antidepressantsMartin M Katz
Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA
Int J Neuropsychopharmacol 7:471-9. 2004..Thus, the Brief MV, in uncovering underlying behavioural actions, represents an important addition to the current unidimensional HAMD approach in drug research... - Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depressionMartin M Katz
Department of Psychiatry, The University of Texas Health Science Center, San Antonio, TX, USA
Neuropsychopharmacology 29:566-79. 2004..Early drug-specific behavioral changes were highly predictive of ultimate clinical response to the different ADs, results that could eventually be applied directly to clinical practice...